China – China announces new guidelines for oncology drugmakers

The US has long been the leader in research and development in oncology, but homegrown Chinese drugmakers have jumped one hurdle after another in making a name for themselves. Now, the Chinese government is erecting new hurdles for its native industry to leap, and — at least for now — it’s putting a slight chill on the field.

The Chinese health authority NMPA’s Center for Drug Evaluation released new guidance on oncology R&D late last week, offering a new gold standard for how homegrown drugmakers should determine clinical efficacy amid a booming field for drug innovation, according to draft documents…